Millions may be suffering from a little-known condition that could be hiding behind common symptoms like heartburn, headaches ...

MCAS refers to a group of disorders characterized by multisystem symptoms resulting from the accumulation of altered mast cells and/or abnormal mast cell mediator release, causing repeated ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

MCAS refers to a group of disorders characterized by multisystem symptoms resulting from the accumulation of altered mast cells and/or abnormal mast cell mediator release, causing repeated ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology <l ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

Sanofi to acquire US-based biopharma company, Blueprint Medicines for up to $9.5 billion: Paris Tuesday, June 3, 2025, 09:00 Hrs [IST] Sanofi and Blueprint Medicines Corporation ( ...

Sanofi S.A. (Paris, France) and Blueprint Medicines Corp. (Blueprint), a U.S.-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi and Blueprint Medicines Corporation have entered into an agreement under which Sanofi plans to acquire the US biopharmaceutical company Blueprint for 9.1 billion dollars.

We had previously suggested that a threshold level of mast cell content (tryptase, chymase and so on) exists [15] above which it can provoke coronary artery spasm and/or plaque erosion or rupture.